These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22971456)
41. Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Gao MZ; Zhao XM; Sun ZG; Hong Y; Zhao LW; Zhang HQ Fertil Steril; 2011 Feb; 95(2):673-8. PubMed ID: 21067720 [TBL] [Abstract][Full Text] [Related]
42. Persistent megalocystic ovaries after ovarian hyperstimulation syndrome in a postpartum patient with polycystic ovarian syndrome: a case report. Shi J; Ren X; Tian Q; Sun A; Chen R J Ovarian Res; 2018 Sep; 11(1):79. PubMed ID: 30201001 [TBL] [Abstract][Full Text] [Related]
43. Distinction between early and late ovarian hyperstimulation syndrome. Mathur RS; Akande AV; Keay SD; Hunt LP; Jenkins JM Fertil Steril; 2000 May; 73(5):901-7. PubMed ID: 10785214 [TBL] [Abstract][Full Text] [Related]
44. Management ofanovulatory infertility associated with polycystic ovary syndrome (PCOS). Sukcharoen N J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S182-8. PubMed ID: 21213521 [TBL] [Abstract][Full Text] [Related]
45. Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. Orvieto R; Voliovitch I; Fishman P; Ben-Rafael Z Hum Reprod; 1995 Jan; 10(1):24-7. PubMed ID: 7745063 [TBL] [Abstract][Full Text] [Related]
46. Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? Geva E; Amit A; Lessing JB; Lerner-Geva L; Daniel Y; Yovel I; Azem F; Barak V J Reprod Med; 1999 Feb; 44(2):91-6. PubMed ID: 10853438 [TBL] [Abstract][Full Text] [Related]
47. Androstenedione as a predictor of ovarian hyperstimulation syndrome. Gustafson O; Carlström K; Nylund L Hum Reprod; 1992 Aug; 7(7):918-21. PubMed ID: 1430128 [TBL] [Abstract][Full Text] [Related]
48. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114 [TBL] [Abstract][Full Text] [Related]
49. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Pau E; Alonso-Muriel I; Gómez R; Novella E; Ruiz A; García-Velasco JA; Simón C; Pellicer A Hum Reprod; 2006 Jun; 21(6):1453-60. PubMed ID: 16488907 [TBL] [Abstract][Full Text] [Related]
50. Dynamic changes of the immunoglobulins in patients with severe ovarian hyperstimulation syndrome: efficacy of a novel treatment using peritoneo-venous shunt. Takamizawa S; Shibahara H; Taneichi A; Obara H; Fujiwara H; Ogawa S; Koike T; Idei S; Sato I Am J Reprod Immunol; 2002 Jan; 47(1):25-30. PubMed ID: 11883746 [TBL] [Abstract][Full Text] [Related]
51. Oocyte quality in patients with severe ovarian hyperstimulation syndrome: a self-controlled clinical study. Fábregues F; Peñarrubia J; Vidal E; Casals G; Vanrell JA; Balasch J Fertil Steril; 2004 Oct; 82(4):827-33. PubMed ID: 15482755 [TBL] [Abstract][Full Text] [Related]
52. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Rogolino A; Coccia ME; Fedi S; Gori AM; Cellai AP; Scarselli GF; Prisco D; Abbate R Blood Coagul Fibrinolysis; 2003 Apr; 14(3):277-82. PubMed ID: 12695751 [TBL] [Abstract][Full Text] [Related]
53. [In vitro maturation--a potential approach of infertility treatment of patients with PCOS]. Kostov I; Ingilizova G Akush Ginekol (Sofiia); 2013; 52(4):25-8. PubMed ID: 24283075 [TBL] [Abstract][Full Text] [Related]
54. [Association of the clinical characteristics and the IVF-ET outcome in infertile women with polycystic ovarian syndrome of different subtypes]. Li M; Song J; Chen SL; Luo C; Ni YP; Wang QL; Zheng HY; Wu FR Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb; 29(2):224-7. PubMed ID: 19246284 [TBL] [Abstract][Full Text] [Related]
55. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Gurbuz AS; Gode F; Ozcimen N; Isik AZ Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114 [TBL] [Abstract][Full Text] [Related]
56. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393 [TBL] [Abstract][Full Text] [Related]
57. Predictive factors for recovery time in patients suffering from severe OHSS. Nouri K; Tempfer CB; Lenart C; Windischbauer L; Walch K; Promberger R; Ott J Reprod Biol Endocrinol; 2014 Jul; 12():59. PubMed ID: 24996451 [TBL] [Abstract][Full Text] [Related]
58. Severe ovarian hyperstimulation syndrome in a naturally conceived singleton pregnancy after ovulation induction: a case report. Yang F; Hu H; He PZ; Zhang M; Qian Y; Li Y Clin Exp Obstet Gynecol; 2017; 44(2):292-295. PubMed ID: 29746043 [TBL] [Abstract][Full Text] [Related]
59. Management and obstetric outcome of ovarian hyperstimulation syndrome. Zareen N J Coll Physicians Surg Pak; 2008 Feb; 18(2):86-90. PubMed ID: 18454892 [TBL] [Abstract][Full Text] [Related]